Menu
Recruiting NCT07675616

Hemodynamic Effect of Dexmedetomidine Versus Magnesium Sulphate as an Adjuvant to Lidocaine in Preemptive Peribulbar Block in Patients Undergoing Dacryocystorhinostomy Under General Anesthesia

No phase Interventional Hemodynamic Effect Dexmedetomidine Magnesium Sulphate Lidocaine

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Lidocaine + Dexmedetomidine, Lidocaine + Magnesium sulphate, Lidocaine.
Who it may be relevant to
Registry conditions: Hemodynamic Effect, Dexmedetomidine, Magnesium Sulphate, Lidocaine. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Hemodynamic Effect of Dexmedetomidine Versus Magnesium Sulphate as an Adjuvant to Lidocaine in Preemptive Peribulbar Block in Patients Undergoing Dacryocystorhinostomy Under General Anesthesia: A Randomized Controlled Trial

Overview

This study aims to compare the hemodynamic effect of dexmedetomidine and magnesium sulphate as an adjuvant to lidocaine in preemptive peribulbar block in patients undergoing Dacryocystorhinostomy (DCR) under general anaesthesia (GA) .

Detailed description

Dacryocystorhinostomy (DCR) is a delicate ophthalmic surgical procedure aimed at reestablishing the patency of the nasolacrimal duct in patients suffering from nasolacrimal duct obstruction (NLDO).

Magnesium is a non-competitive N-methyl-D-aspartate (NMDA) receptors antagonist, and it can decrease the excitatory post synaptic currents produced by activation of NMDA receptors and it inhibits voltage gated calcium channels.

Dexmedetomidine alpha-2 agonist, which stimulates both central and peripheral alpha-2 receptors which inhibits neuronal firing and inhibits release of C-fibers transmitters such as norepinephrine which inhibits nerve fiber action potential and explains the antinociceptive effects of dexmedetomidine.

Interventions

  • Drug Lidocaine + Dexmedetomidine
    Patients will receive 5 ml of lidocaine 2% + 50 µg dexmedetomidine, with a total volume of 7 ml.
  • Drug Lidocaine + Magnesium sulphate
    Patients will receive 5 ml of lidocaine 2% + 100 mg magnesium sulphate 10%, with a total volume of 7 ml.
  • Drug Lidocaine
    Patients will receive 7 ml of lidocaine 2% with no further additives.

Primary outcome measures

  • Change in mean arterial blood pressure [Time frame: Till the end of surgery (Up to 2 hours)]
Secondary outcome measures (4)
  • Heart rate [Time frame: Till the end of surgery (Up to 2 hours)]
  • Oxygen saturation [Time frame: Till the end of surgery (Up to 2 hours)]
  • Degree of patient satisfaction [Time frame: 24 hours postoperatively]
  • Degree of surgeon satisfaction [Time frame: 24 hours postoperatively]

Eligibility criteria

Inclusion criteria

  • Age ≥ 18 years.
  • Both sexes.
  • American Society of Anesthesiologists (ASA) physical status I or II.
  • Undergoing elective Dacryocystorhinostomy (DCR) surgery under general anesthesia.

Exclusion criteria

  • Patients have local infection.
  • Allergic reaction or complications of the local anaesthesia (LA).
  • Coagulopathy defined as international normalized ratio (INR) > 1.5, platelet count < 100,000/mm³, or ongoing anticoagulant therapy not adequately discontinued.
  • Uncontrolled systemic disease, defined as poorly controlled hypertension \[systolic blood pressure (SBP) > 160 mmHg\], uncontrolled diabetes mellitus (HbA1c > 8.5%), unstable ischemic heart disease, or decompensated hepatic or renal disease.
  • Uncooperative patients.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Cairo University — Cairo

Identifiers

NCT: NCT07675616 · MS-141-2026 (14-5-2026)

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗